Literature DB >> 7119200

Post-therapy CT-detected mass in lymphoma patients: is it viable tissue?

E Lewis, M E Bernardino, P G Salvador, F F Cabanillas, P A Barnes, J L Thomas.   

Abstract

The demonstration by computed tomography (CT) of enlarged nodes and/or masses in lymphoma patients has been interpreted as indicating that active disease is present. Four cases are presented in which either biopsy or laparotomy of a CT-detected mass after therapy revealed fibrous tissue with no evidence of viable neoplasm. These four cases demonstrate the possible pitfall of diagnosing viable lymphoma in masses detected by CT after therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7119200     DOI: 10.1097/00004728-198208000-00025

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  10 in total

Review 1.  Assessment of response to therapy using conventional imaging.

Authors:  Sheila C Rankin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-27       Impact factor: 9.236

2.  Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study.

Authors:  M Bendini; C Zuiani; M Bazzocchi; G Dalpiaz; F Zaja; E Englaro
Journal:  MAGMA       Date:  1996 Sep-Dec       Impact factor: 2.310

3.  Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

Authors:  Lale Kostakoglu; Heiko Schöder; Jeffrey L Johnson; Nathan C Hall; Lawrence H Schwartz; David J Straus; Ann S LaCasce; Sin-Ho Jung; Nancy L Bartlett; George P Canellos; Bruce D Cheson
Journal:  Leuk Lymphoma       Date:  2012-08-28

4.  Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

Authors:  Elise A Olsen; Sean Whittaker; Youn H Kim; Madeleine Duvic; H Miles Prince; Stuart R Lessin; Gary S Wood; Rein Willemze; Marie-France Demierre; Nicola Pimpinelli; Maria Grazia Bernengo; Pablo L Ortiz-Romero; Martine Bagot; Teresa Estrach; Joan Guitart; Robert Knobler; José Antonio Sanches; Keiji Iwatsuki; Makoto Sugaya; Reinhard Dummer; Mark Pittelkow; Richard Hoppe; Sareeta Parker; Larisa Geskin; Lauren Pinter-Brown; Michael Girardi; Günter Burg; Annamari Ranki; Maartan Vermeer; Steven Horwitz; Peter Heald; Steve Rosen; Lorenzo Cerroni; Brigette Dreno; Eric C Vonderheid
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

Review 5.  Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas.

Authors:  N George Mikhaeel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

6.  Comparison of CT and MRI in the evaluation of therapeutic response in thoracic Hodgkin disease.

Authors:  S S Elkowitz; J C Leonidas; M Lopez; I Cherick; R G Schiff; G Karayalcin; P Lanzkowsky
Journal:  Pediatr Radiol       Date:  1993

7.  [Response criteria for malignant lymphoma].

Authors:  M K Ganten
Journal:  Radiologe       Date:  2012-04       Impact factor: 0.635

8.  Magnetic resonance imaging for the assessment of residual masses after treatment of non-Hodgkin's lymphomas.

Authors:  C Montalbán; J L Rodríguez-García; L Mazairas; I Ayala; J Marcos-Robles
Journal:  Postgrad Med J       Date:  1992-08       Impact factor: 2.401

9.  67Ga scan for evaluating response to therapy in malignant lymphoma.

Authors:  K Koizumi; H Ogata; G Uchiyama; T Araki; T Hihara; S Monzawa; K Kachi; M Matsusako
Journal:  Eur J Nucl Med       Date:  1989

10.  Lymphoma: a clinical view.

Authors:  M Hill; N Maisey
Journal:  Cancer Imaging       Date:  2000-10-11       Impact factor: 3.909

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.